Developmental Therapeutics

发育治疗学

基本信息

批准号：
7726748
负责人：
Geoffrey R Weiss
金额：
$ 2.36万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7726748
关键词：
Advanced Malignant Neoplasm Agreement Angiogenesis Inhibitors Antibody Therapy Area Aromatase Inhibitors Basic Science Biological Markers Cancer Center Cancer Center Support Grant Cancer Control Research Program Cancer Research Project Clinic Clinical Clinical Investigator Clinical Protocols Clinical Research Clinical Trials Collaborations Colorectal Cancer Community Clinical Oncology Program Comprehensive Cancer Center Core Facility Development Developmental Therapeutics Program Disease Doctor of Medicine Equipment and supply inventories Faculty Fostering Genitourinary system Goals Grant Growth Head and Neck Cancer Health system Hematologic Neoplasms Hematology Human Image Imaging technology Immunotherapy Internal Medicine Investigation Investments Knowledge Laboratories Laboratory Research Laboratory Scientists Lead Leadership Link Malignant Female Reproductive System Neoplasm Malignant Neoplasms Malignant neoplasm of ovary Malignant neoplasm of prostate Malignant neoplasm of urinary bladder Mentors Mentorship Mission Modeling Molecular Movement NCI Center for Cancer Research Numbers Occupational activity of managing finances Operative Surgical Procedures Patients Phase Pilot Projects Plant Roots Prevention Primary Lesion Protocols documentation Public Health Publications Published Comment Radiation Recruitment Activity Renal Cell Carcinoma Research Research Infrastructure Research Personnel Research Project Grants Resource Sharing Resources Science Scientist Source Structure Talents Therapeutic Thoracic Oncology Time Translational Research Tyrosine Kinase Inhibitor Universities Vaccines Virginia Woman Work Writing anticancer research base cancer genetics cytokine therapy data management design genetic epidemiology implementation science innovation interest malignant breast neoplasm melanoma member neoplasm resource neuro-oncology novel oncology programs

项目摘要

Program 7: Developmental Therapeutics has, as its principal goal, the development and implementation of human cancer clinical research based on discovery science. The Program emphasizes two subprograms, 1) Immune Therapy and 2) Targeted Therapy, Biomarkers and Imaging. The two subprograms are led respectively by Craig L. Slingluff, M.D., Department of Surgery, and by Geoffrey R. Weiss, M.D., Department of Internal Medicine. The Program has 49 members from 19 different departments or divisions of the University of Virginia Health System. Investigators of this Program are supported by $3.6 million from the NCI and by a total of $9.2 million from all sources. The goals of Program 7 include the development of investigator-initiated clinical trials based in the discovery science of laboratories within the Cancer Center, expansion of the Clinical Trials Office as a comprehensive resource for support of the clinical investigator, and recruitment of new clinical scientists to the program. The Immune Therapy Subprogram is invested in a broad array of clinical trials evaluating multipeptide vaccines in malignant melanoma, colorectal cancer and ovarian cancer, antibody therapies of hematological malignancies, and cytokine therapies of melanoma and renal cell carcinoma. Investigators of the Targeted Therapy, Biomarkers and Imaging Subprogram are evaluating tyrosine kinase inhibitors, angiogenesis inhibitors and aromatase inhibitors with accompanying collaborative studies to confirm "proof-of-principle" impact of therapy upon the intended targets. Novel biomarkers of early and advanced cancer are sought in bladder cancer, breast cancer, gynecologic cancers, and melanoma. New imaging technologies are being applied to identification of breast cancer lesions and primary prostate cancer, while imaging technology is applied to radiation planning for helical tomotherapy in head and neck cancer. Since the last renewal, members of Program 7 had a total of 499 publications, of which 25% were intra-programmatic and 32% were inter-programmatic.

计划7：发育疗法作为其主要目标，是发展和基于发现科学的人类癌症临床研究的实施。该计划强调两个子程序，1）免疫治疗和2）靶向治疗，生物标志物和成像。两个子程序分别由手术系M.D. Craig L. Slingluff和Geoffrey R.领导。魏斯，医学博士，内科。该计划有来自19个不同部门的49名成员或弗吉尼亚大学卫生系统的分界。该计划的调查人员得到3.6美元的支持来自NCI的百万美元，所有来源的总计920万美元。程序7的目标包括基于研究人员发起的临床试验的开发，基于实验室的发现科学癌症中心，扩展临床试验办公室，作为支持临床的综合资源研究人员，并招募了该计划的新临床科学家。免疫治疗子图是投资了一系列评估恶性黑色素瘤多肽疫苗的临床试验癌症和卵巢癌，血液恶性肿瘤的抗体疗法以及细胞因子疗法黑色素瘤和肾细胞癌。靶向疗法，生物标志物和成像的研究者子程序评估酪氨酸激酶抑制剂，血管生成抑制剂和芳香酶抑制剂的抑制剂随附的协作研究以确认治疗对预期的“原理证明”影响目标。在膀胱癌，乳腺癌，妇科癌和黑色素瘤。新的成像技术正在应用于乳房的识别癌症病变和原发性前列腺癌，而成像技术则用于辐射计划头颈癌中的螺旋疗法。自上次续签以来，计划7的成员总共有 499个出版物，其中25％是概括性的，32％是跨编程间的。